Scleroderma (Systemic Sclerosis) treatment options (2026): standard, alternative & regenerative
Systemic sclerosis (scleroderma) is an autoimmune disease involving fibrosis and vascular and immune dysfunction that may affect skin and internal organs. Two very different approaches must not be conflated. Autologous haematopoietic stem-cell transplantation (HSCT) is an intensive specialist treatment considered in selected people with severe, early diffuse cutaneous systemic sclerosis after careful cardiopulmonary risk assessment. Placental or other mesenchymal stromal cell (MSC) products remain investigational and have not established the same clinical role. The registry table on this page lists relevant studies and their current recruitment status.
Standard & first-line treatment for Scleroderma (Systemic Sclerosis)
Established care should follow a diagnosis-specific plan made with a suitably qualified clinician. Depending on the condition, that plan may include cause-directed treatment, authorised medicines or procedures, rehabilitation, monitoring and supportive care. Selection depends on severity, other illnesses, current medicines, contraindications and the person's goals. An experimental product must not displace urgent or time-sensitive established care.
Alternative & complementary options
Complementary approaches are not interchangeable with established treatment. Evidence, product quality, interactions and practitioner regulation differ by method and condition. Ask what outcome was studied, in which population, against which comparator and for how long. Discuss supplements, devices and procedures with the treating team, and do not use testimonials or a package label as evidence of benefit.
Regenerative and cell interventions: evidence and regulatory status
Randomised evidence and specialist recommendations support considering autologous HSCT for carefully selected severe early diffuse disease, while recognising substantial treatment-related risk. That evidence cannot be transferred to placental MSC infusion: the products, conditioning, mechanism, risks and endpoints are fundamentally different. MSC studies remain early and heterogeneous. No combined response rate is published here. The registered studies and their own prespecified endpoints are listed in the registry table on this page. Treat this as product-specific research, not as a generic treatment class. Verify the exact product, source, processing, manufacturer, dose, route, indication, regulator or ethics approval, comparator, endpoints and adverse-event plan. See the condition evidence page for registry and study context.
Scleroderma (Systemic Sclerosis) treatment options compared
| Option | Type | Evidence | Cost information | Invasiveness | Recovery |
|---|---|---|---|---|---|
| Diagnostic and specialist assessment | Standard | Required to define diagnosis, cause, severity and suitability | Varies by tests, country, coverage and provider; request an itemised quote | Depends on the assessment | No universal timeline |
| Guideline-directed established care | Standard | Condition- and patient-specific; use the current clinical guideline | Varies by treatment, country and coverage; request an itemised quote | Depends on the selected treatment | Defined by the selected established treatment |
| Rehabilitation, monitoring and supportive care | Standard / supportive | Condition- and goal-specific | Varies by programme, duration, country and coverage | Usually low, but programme-specific | Ongoing and goal-specific |
| Cell, exosome or other regenerative intervention | Authorised clinical trial only / research | Investigational; exact product and indication must be verified | A commercial price is not evidence of approval, safety or efficacy | Depends on collection, processing and administration | Defined by the authorised protocol; benefit is uncertain |
Scleroderma (Systemic Sclerosis) treatment — common questions
How should established options be selected?
Start with a confirmed diagnosis and an independent clinician who can apply the current condition-specific guideline. Compare expected benefits, harms, burden, alternatives and what happens without treatment. Choice cannot be reduced to a universal ranking or a commercial package.
Is a regenerative product approved for this condition?
No placental MSC product is FDA-approved for systemic sclerosis. An IND-authorised MSC trial or registry listing is not product approval. Autologous HSCT is a specialist transplantation procedure rather than an FDA-approved MSC medicine and is considered according to clinical evidence, guidelines and centre-specific eligibility. In Europe, trial authorisation is distinct from EMA marketing authorisation.
How should cost and value be assessed?
Costs for specialist autologous HSCT and investigational MSC infusion are not comparable. HSCT involves mobilisation, conditioning chemotherapy, hospital care and prolonged monitoring; an MSC infusion is a different experimental product and procedure. Private quotations may exclude pre-treatment organ assessment, standard systemic-sclerosis care, travel and management of complications. Patients should obtain an itemised written quote and written confirmation of sponsor, insurer and patient responsibilities without treating price as evidence of benefit. Do not generalise reimbursement across HSCT and investigational MSC therapy. Coverage for specialist autologous HSCT depends on clinical eligibility, health system, insurer and centre; investigational MSC costs are trial- and policy-specific. Obtain written confirmation covering assessment, hospital care, the investigational product, follow-up, travel and treatment of complications. Placental MSC infusion is not an evidence-based lower-risk substitute for autologous HSCT or established systemic-sclerosis treatment. Investigational MSC access is most defensible within a registered clinical trial. Autologous HSCT may be considered for carefully selected severe early diffuse disease only through a specialist multidisciplinary programme after explicit assessment of treatment-related mortality and cardiopulmonary risk.
Sources & further reading
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
- Open clinical trials for Scleroderma (Systemic Sclerosis) (ClinicalTrials.gov) ↗
- Peer-reviewed research on PubMed ↗
- ISSCR patient guide — what to ask ↗
- FDA consumer warning on stem-cell therapies ↗
- EMA — advanced-therapy (ATMP) framework ↗
Educational overview only; not medical advice. Verify current guidance, regulatory status and treatment options with the cited authorities and an independent qualified physician.
More on this condition
- Scleroderma (Systemic Sclerosis): cell-therapy evidence and registered trials
- How much does stem cell therapy for Scleroderma (Systemic Sclerosis) cost? (2026)
- Scleroderma (Systemic Sclerosis) stem cell therapy — your questions answered (2026)
- Scleroderma (Systemic Sclerosis): cell-therapy evidence by therapy class
- MSC vs HSCT for Scleroderma (Systemic Sclerosis): what the registries show